Advocacy intelligence hub — real-time data for patient organizations
Cyfendus: FDA approved
post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs
BioThrax: FDA approved
For post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance2
Cyfendus
Emergent Product Development Gaithersburg, Inc.
BioThrax
Emergent BioDefense Operations Lansing LLC
Cyfendus
(Anthrax Vaccine Adsorbed, Adjuvanted)Orphan drugEmergent Product Development Gaithersburg, Inc.
Browse all OBSOLETE: Disease predisposing to age-related macular degeneration news →
View all OBSOLETE: Disease predisposing to age-related macular degeneration specialists →